TipRanks
Advertisement
Advertisement

HK:9887 Stock Latest News

Nanjing Leads Biolabs Wins Second U.S. FDA Fast Track for Cancer Drug LBL-024
Company AnnouncementsNanjing Leads Biolabs Wins Second U.S. FDA Fast Track for Cancer Drug LBL-024
1d ago
9887
Nanjing Leads Biolabs Wins Japan Orphan Drug Status for Cancer Antibody LBL-024
PremiumCompany Announcements
Nanjing Leads Biolabs Wins Japan Orphan Drug Status for Cancer Antibody LBL-024
15d ago
9887
Nanjing Leads Biolabs Wins Top ESMO Slots for Key Cancer Trials
PremiumCompany Announcements
Nanjing Leads Biolabs Wins Top ESMO Slots for Key Cancer Trials
21d ago
9887
Nanjing Leads Biolabs’ Bispecific Antibody LBL-024 Shows Strong First-Line NSCLC Data
PremiumCompany Announcements
Nanjing Leads Biolabs’ Bispecific Antibody LBL-024 Shows Strong First-Line NSCLC Data
29d ago
9887
Leads Biolabs Initiated With Buy as Registrational LBL-024 Sets Path to 1H27 Approval and Pan-Tumor Growth
PremiumRatings
Leads Biolabs Initiated With Buy as Registrational LBL-024 Sets Path to 1H27 Approval and Pan-Tumor Growth
1M ago
Nanjing Leads Biolabs Advances Next-Generation Immuno-Oncology Pipeline Toward First-in-Class Approval
PremiumCompany AnnouncementsNanjing Leads Biolabs Advances Next-Generation Immuno-Oncology Pipeline Toward First-in-Class Approval
1M ago
9887
Nanjing Leads Biolabs Advances Key Immunotherapy LBL-024 in Esophageal Cancer Trial
Premium
Company Announcements
Nanjing Leads Biolabs Advances Key Immunotherapy LBL-024 in Esophageal Cancer Trial
2M ago
9887
Nanjing Leads Biolabs’ PD-L1/4-1BB Cancer Drug Wins Priority Review in China
Premium
Company Announcements
Nanjing Leads Biolabs’ PD-L1/4-1BB Cancer Drug Wins Priority Review in China
2M ago
9887
Leads Biolabs touts promising Phase II data for NSCLC bispecific antibody LBL-024
PremiumCompany Announcements
Leads Biolabs touts promising Phase II data for NSCLC bispecific antibody LBL-024
2M ago
9887
Oblenio Exercises License Option for Nanjing Leads Biolabs’ Autoimmune Drug LBL-051
PremiumCompany Announcements
Oblenio Exercises License Option for Nanjing Leads Biolabs’ Autoimmune Drug LBL-051
2M ago
9887
Nanjing Leads Biolabs Sets Board Meeting to Approve Interim Results and Consider Dividend
PremiumCompany Announcements
Nanjing Leads Biolabs Sets Board Meeting to Approve Interim Results and Consider Dividend
2M ago
9887
Nanjing Leads Biolabs Advances Key Liver Cancer Trial for Opamtistomig
PremiumCompany Announcements
Nanjing Leads Biolabs Advances Key Liver Cancer Trial for Opamtistomig
2M ago
9887
Nanjing Leads Biolabs Advances Autoimmune Drug LBL-051 Into First-in-Human Trial
PremiumCompany AnnouncementsNanjing Leads Biolabs Advances Autoimmune Drug LBL-051 Into First-in-Human Trial
2M ago
9887
Nanjing Leads Biolabs Wins IND Nod for Bispecific Antibody in Metastatic Colorectal Cancer
Premium
Company Announcements
Nanjing Leads Biolabs Wins IND Nod for Bispecific Antibody in Metastatic Colorectal Cancer
2M ago
9887
Nanjing Leads Biolabs Completes Phase II Enrollment for Opamtistomig in Biliary Tract Cancer
Premium
Company Announcements
Nanjing Leads Biolabs Completes Phase II Enrollment for Opamtistomig in Biliary Tract Cancer
2M ago
9887
Nanjing Leads Biolabs CEO Extends Lock-Up, Signaling Confidence in Long-Term Prospects
PremiumCompany Announcements
Nanjing Leads Biolabs CEO Extends Lock-Up, Signaling Confidence in Long-Term Prospects
3M ago
9887
Nanjing Leads Biolabs Wins Key ESMO Slots as Flagship Immunotherapy Assets Gain Momentum
PremiumCompany Announcements
Nanjing Leads Biolabs Wins Key ESMO Slots as Flagship Immunotherapy Assets Gain Momentum
3M ago
9887
Nanjing Leads Biolabs’ LBL-024 for EP-NEC Enters China Priority Review
PremiumCompany Announcements
Nanjing Leads Biolabs’ LBL-024 for EP-NEC Enters China Priority Review
3M ago
9887
Nanjing Leads Biolabs Grants Over 2.25 Million H Share Awards to Staff Under Incentive Scheme
PremiumCompany Announcements
Nanjing Leads Biolabs Grants Over 2.25 Million H Share Awards to Staff Under Incentive Scheme
3M ago
9887
Nanjing Leads Biolabs’ JV Secures US$62 Million to Advance Trispecific Autoimmune Therapy
PremiumCompany AnnouncementsNanjing Leads Biolabs’ JV Secures US$62 Million to Advance Trispecific Autoimmune Therapy
4M ago
9887
Nanjing Leads Biolabs Completes H Share Full Circulation to Boost Liquidity
Premium
Company Announcements
Nanjing Leads Biolabs Completes H Share Full Circulation to Boost Liquidity
4M ago
9887
Nanjing Leads Biolabs Showcases Promising Opamtistomig Data Ahead of 2026 Lung Cancer Summit
Premium
Company Announcements
Nanjing Leads Biolabs Showcases Promising Opamtistomig Data Ahead of 2026 Lung Cancer Summit
5M ago
9887

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >